Follow Us TR

News Details

Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101

About Satsuma Pharmaceuticals, Inc.
  • NASDAQ: $STSA
  • Notified: $25.78
  • 16:01 EDT

Price Chart